MBM Wealth Consultants’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$3.21M Buy
12,272
+271
+2% +$69.5K 0.59% 28
2026
Q2
$3.02M Buy
12,001
+312
+3% +$67.1K 0.58% 25
2026
Q1
$2.54M Buy
11,689
+270
+2% +$59.9K 0.58% 25
2025
Q4
$2.61M Sell
11,419
-256
-2% -$58.3K 0.62% 24
2025
Q3
$2.7M Sell
11,675
-14
-0.1% -$2.85K 0.67% 22
2025
Q2
$2.17M Buy
11,689
+97
+0.8% +$18K 0.58% 25
2025
Q1
$2.43M Buy
11,592
+246
+2% +$47.8K 0.72% 20
2024
Q4
$2.04M Buy
11,346
+83
+0.7% +$15.3K 0.61% 23
2024
Q3
$2.22M Sell
11,263
-133
-1% -$24.8K 0.7% 20
2024
Q2
$1.91M Buy
11,396
+163
+1% +$27K 0.65% 21
2024
Q1
$2.05M Sell
11,233
-68
-0.6% -$11.7K 0.72% 19
2023
Q4
$1.85M Sell
11,301
-165
-1% -$24.1K 0.69% 20
2023
Q3
$1.7M Buy
11,466
+108
+1% +$15.9K 0.74% 21
2023
Q2
$1.53M Buy
11,358
+737
+7% +$108K 0.66% 23
2023
Q1
$1.77M Hold
10,621
– – 0.72% 20
2022
Q4
$1.72M Buy
10,621
+94
+0.9% +$14.4K 0.8% 19
2022
Q3
$1.46M Buy
10,527
+472
+5% +$67.7K 0.7% 19
2022
Q2
$1.54M Sell
10,055
-297
-3% -$45.4K 0.75% 20
2022
Q1
$1.68M Buy
10,352
+20
+0.2% +$2.9K 0.7% 25
2021
Q4
$1.4M Buy
10,332
+18
+0.2% +$2.13K 0.58% 27
2021
Q3
$1.11M Sell
10,314
-14
-0.1% -$1.6K 0.51% 34
2021
Q2
$1.16M Sell
10,328
-34
-0.3% -$3.83K 0.55% 32
2021
Q1
$1.12M Sell
10,362
-488
-4% -$52.2K 0.57% 34
2020
Q4
$1.16M Sell
10,850
-37
-0.3% -$3.56K 0.63% 28
2020
Q3
$953K Sell
10,887
-127
-1% -$12K 0.61% 28
2020
Q2
$1.08M Sell
11,014
-4,787
-30% -$421K 0.76% 25
2020
Q1
$1.25M Sell
15,801
-157
-1% -$13.4K 1.03% 23
2019
Q4
$1.41M Sell
15,958
-1,326
-8% -$110K 1.05% 26
2019
Q3
$1.31M Buy
17,284
+194
+1% +$13.3K 1.03% 26
2019
Q2
$1.26M Buy
17,090
+414
+2% +$32.5K 1.05% 26
2019
Q1
$1.34M Buy
16,676
+342
+2% +$28K 1.18% 25
2018
Q4
$1.51M Hold
16,334
– – 1.47% 21

Other funds holding ABBV

MBM Wealth Consultants's ABBV Position: Q3 2026 in Review

MBM Wealth Consultants increased its AbbVie (ABBV) stake by 2.3% in Q3 2026, buying an estimated $69.5K and bringing the position to 12,272 shares worth $3.21M. The position accounts for 0.59% of the portfolio, ranked #28.

MBM Wealth Consultants first reported a position in ABBV in Q4 2018 and has held it in 32 quarters since. 4,281 funds tracked by Wall St. Rank hold ABBV as of Q3 2026.

  • MBM Wealth Consultants held 12,272 shares of AbbVie worth $3.21M as of Q3 2026.
  • MBM Wealth Consultants bought 271 AbbVie shares in Q3 2026, an estimated $69.5K.
  • AbbVie made up 0.59% of MBM Wealth Consultants's portfolio in Q3 2026, its #28 holding.
  • MBM Wealth Consultants first reported a position in AbbVie in Q4 2018 and has held it in 32 quarters since.
  • 4,281 funds tracked by Wall St. Rank held AbbVie as of Q3 2026.

Based on MBM Wealth Consultants's 13F filing for Q3 2026, filed 20 Oct 2026.